New hope for advanced HER2 cancers? early trial combines novel drug with standard therapy
Disease control
Ongoing
This early-stage study is testing a new drug called ELVN-002 combined with trastuzumab (and sometimes chemotherapy) in adults with advanced HER2-positive solid tumors, including breast, colorectal, and gastric cancers. The main goals are to find the safest dose and understand sid…
Phase: PHASE1 • Sponsor: Enliven Therapeutics • Aim: Disease control
Last updated May 13, 2026 16:01 UTC